Bicycle Therapeutics plc (BCYC)

Market Cap	1.41B
Revenue (ttm)	36.90M
Net Income (ttm)	-166.28M
Shares Out	69.05M
EPS (ttm)	-3.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	270,591
Open	20.49
Previous Close	20.48
Day's Range	20.15 - 20.90
52-Week Range	13.31 - 28.67
Beta	0.89
Analysts	Buy
Price Target	40.13 (+97.1%)
Earnings Date	Oct 31, 2024

About BCYC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2019
• Employees: 284
• Stock Exchange: NASDAQ
• Ticker Symbol: BCYC
• Website: https://www.bicycletherapeutics.com

Financial Performance

In 2023, Bicycle Therapeutics's revenue was $26.98 million, an increase of 86.52% compared to the previous year's $14.46 million. Losses were -$180.66 million, 60.3% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is $40.13, which is an increase of 97.10% from the latest price.

Price Target

$40.13

(97.10% upside)

Analyst Consensus: Buy